Globally, CVD kills more than 20.5 million people every year, with 85 per cent of these deaths caused by heart attacks and ...
"The pressure was relentless – to fix, shrink and manage a body that medicine had always treated as a problem to solve." ...
AbbVie (NYSE: ABBV) today announced plans to launch ELAHERE® (mirvetuximab soravtansine-gynx) in the U.K. at a list price equal to the U.S., reflecting the advanced innovation and value of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback